Aberrant expression/activation PRKDC has been reported to be associated with chemoresistance in a variety of tumors including glioma, oral squamous cell carcinoma, ovarian cancer and breast cancer due to its function in DNA damage repair [26, 27, 35–37]. This evidence concerns the gene PRKDC and glioma.